ENYGLID

This brand name is authorized in Austria, Cyprus, Estonia, Ireland, Lithuania, Poland, UK.

Active ingredients

The drug ENYGLID contains one active pharmaceutical ingredient (API):

1	Repaglinide UNII 668Z8C33LU - REPAGLINIDE
	Repaglinide is a short-acting oral secretagogue. Repaglinide lowers the blood glucose levels acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning β-cells in the pancreatic islets.
	Read more about Repaglinide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ENYGLID Tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BX02	Repaglinide	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BX Other blood glucose lowering drugs, excl. insulins
Discover more medicines within A10BX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1440841, 1440852, 1440863, 1440874, 1440885, 1440896, 1440908, 1440919, 1440920, 1440931, 1440942, 1440953, 1440964, 1440975, 1440986, 1440997, 1441000, 1441011, 1504493, 1504505, 1504516
GB	Medicines & Healthcare Products Regulatory Agency	193068, 193070, 193071, 193072, 193074
LT	Valstybinė vaistų kontrolės tarnyba	1051602, 1051603, 1051604, 1051605, 1051606, 1051607, 1051608, 1051609, 1051610, 1051611, 1051612, 1051613, 1051614, 1051615, 1051616, 1051617, 1051618, 1051619, 1058039, 1058040, 1058041
PL	Rejestru Produktów Leczniczych	100217736, 100217802, 100217825